Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) has a high recurrence rate and limited therapeutic targets. Although coatomer protein complex subunit ζ1 (COPZ1) has been identified as a potential therapeutic target based on non‑oncogene addiction in other types of cancer, its role in HCC progression remains unclear; therefore, COPZ1 expression was evaluated in the present study by immunohistochemistry in 227 resected HCC specimens, and its associations with clinicopathological features and survival were analyzed. In addition, the functional effects of COPZ1 knockdown were assessed in PLC/PRF/5 and HLF HCC cell lines. COPZ1 was highly expressed in 60.3% of tumors, and was independently associated with shorter disease‑free survival (DFS) and overall survival (OS). The COPZ1‑high and COPZ1‑low groups had median DFS times of 12.0 and 24.1 months, and 5‑year OS rates of 63.7 and 80.1%, respectively. COPZ1 knockdown significantly reduced cell proliferation (P<0.001), migration (P<0.001) and invasion (P<0.01). Furthermore, RNA sequencing identified >1,600 differentially expressed genes enriched in unfolded protein response pathways; this was confirmed by a gene set enrichment analysis. In addition, under endoplasmic reticulum stress, COPZ1 knockdown was associated with changes in ER stress‑related proteins. In conclusion, COPZ1 expression is associated with poor postoperative outcomes in HCC and its knockdown can suppress malignant phenotypes in HCC cells, supporting its biological relevance and warranting further investigation of its therapeutic relevance.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: